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Objective: Systemic lupus erythematosus is a relapsing autoimmune disease that 
affects multiple organ systems. T cells play an important role in the pathogenesis of 
lupus, however, early T cell events triggering disease flares are incompletely 
understood. We studied DNA methylation in naïve CD4+ T cells from lupus patients to 
determine if epigenetic remodeling in CD4+ T cells is an early event in lupus flares.  
Methods: A total of 74 lupus patients with disease activity ranging from 0-18 as 
measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were 
included in this study. Naïve CD4+ T cells were isolated from peripheral blood samples 
and DNA extracted for genome-wide methylation assessment. RNA was also extracted 
from a subset of patients to determine the relationship between epigenetic changes and 
transcriptional activity using RNA sequencing and microRNA arrays.  
Results: We demonstrate that naïve CD4+ T cells in lupus undergo an epigenetic pro-
inflammatory shift implicating effector T cell responses in lupus flare. This epigenetic 
landscape change occurs without expression changes of corresponding genes, and 
poises naïve CD4+ T cells for Th2, Th17, and Tfh immune responses, and opposes 
inhibitory TGF-β signaling. Bioinformatics analyses indicate that the epigenetic 
modulator EZH2 might be playing an important role in shifting the epigenetic landscape 
with increased disease activity in lupus naïve CD4+ T cells. Further, the expression of 
miR26a which is sensitive to glucose availability and which targets EZH2 was negatively 
correlated with disease activity in lupus patients.  
Conclusion: An epigenetic landscape shift in naïve CD4+ T cells that favors T cell 
activation and non-Th1 immune responses predates transcriptional activity and 
correlates with lupus activity. A role for EZH2 dysregulation in triggering lupus flares 
warrants further investigation. 
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Systemic lupus erythematosus (SLE or lupus) represents a heterogeneous disease 
group characterized by the production of autoantibodies against cellular nuclear 
components. Lupus is a chronic relapsing disease, characterized by a disease course 
consisting of intermittent flares alternating with periods of relative disease quiescence in 
the majority of affected patients.    
The etiology of lupus remains incompletely understood. A high concordance rate in 
monozygotic compared to dizygotic twins, familiar aggregation, and differences in 
disease prevalence between populations suggests a strong etiological genetic 
component in lupus. This has been demonstrated with a growing list of confirmed 
genetic susceptibility loci in lupus (1, 2). More recently, a role for inherited epigenetic 
changes has also been demonstrated (3). 
With the exception of epigenetic accessibility of interferon-regulated genes in lupus (4), 
and inherited epigenetic changes that are directly influenced by genetic variants in the 
germline (3), DNA methylation changes in lupus T cells have been shown to be 
dynamic. Indeed, CD4+ T cells in lupus patients demonstrate a DNA methylation defect 
that is more pronounced in patients with active compared to inactive disease (5). This is 
explained by defective ERK signaling and reduced expression of the DNA 
methyltransferase enzyme DNMT1 (6). Inducing a DNA methylation defect in T cells 
can result in a lupus-like autoimmune disease in vivo (7, 8).  
DNA methylation plays an important role in T cell differentiation and activation. Naïve 
CD4+ T cells selectively undergo an epigenetic shift rendering the IFNG, IL4-IL5-IL13, 
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and IL17 loci accessible for transcription upon differentiating into Th1, Th2, and Th17 
cells, respectively (9). These key cytokine gene loci are heavily methylated and hence 
transcriptionally silent in naïve CD4+ T cells prior to T cell activation or differentiation 
(9).  
Because DNA methylation changes are generally dynamic, and T cells play an 
important role in the pathogenesis of lupus (10), we sought to determine epigenetic 
changes in CD4+ T cells that correlate with disease activity in lupus patients. We 
focused on naïve CD4+ T cells to understand the earliest T cell epigenetic changes in 
lupus flares that predate T cell activation. We performed RNA sequencing in the same 
cells to determine the relationships between epigenetic changes and transcriptional 
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Patients: Demographics and disease activity 
74 female participants previously diagnosed with lupus were included in this study. All 
patients fulfilled the American College of Rheumatology (ACR) classification criteria for 
SLE (11). The average age of patients in the study was 41 years of age, ranging from 
18 to 66 years. A Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 
score was calculated at the clinical visit concurrently with enrollment in the study and 
blood draw. The SLEDAI scores of patients included in this study ranged from 0 to 18, 
with a mean and median SLEDAI of 3 and 2, respectively. No difference in age was 
present between patients with active disease (SLEDAI ≥ 5) and patients with less active 
disease (SLEDAI <5) (P= 0.21). Of the 74 patients, 49 were taking hydroxychloroquine, 
26 were taking mycophenolate mofetil, 13 were taking azathioprine, and 39 were taking 
glucocorticoids of various doses at the time of sample collection. One patient was taking 
methotrexate, and no patients were receiving cyclophosphamide, cyclosporine, 
leflunomide, tacrolimus, rituximab, belimumab, or IVIG. Patients were recruited at the 
Oklahoma Medical Research Foundation, University of Michigan Health System, and 
Henry Ford Health System. The institutional review boards at the participating 
institutions approved this study. All participants signed an informed consent prior to 
enrollment.  
Naïve CD4+ T cell isolation and purity 
Naïve CD4+ T cells were isolated from whole blood by negative selection using the 
Naïve CD4+ T cell Isolation Kit II, human (Miltenyi Biotec, San Diego, CA, USA) 
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according to manufacturer’s instructions. This kit uses an antibody cocktail to directly 
label the surface of undesired cells which are then bound to magnetic beads, allowing 
unlabeled naïve CD4+ T cells to be separated. The purity of the isolated populations 
was confirmed using surface protein staining and flow cytometry as CD3+, CD4+ and 
CD45RA+ using human FITC-conjugated human anti-CD3, human PE-conjugated anti-
CD4, and human Pacific Blue-conjugated anti-CD45RA antibodies (BioLegend, San 
Diego, CA, USA). Cell population purity for all samples included in this study was >95%.  
DNA and RNA extraction 
Genomic DNA was extracted from isolated naïve CD4+ T cell populations using the 
DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA). Total RNA was also 
extracted simultaneously by lysing cells in TRIzol Reagent (ThermoFisher Scientific, 
Grand Island, NY, USA) and then purified using Direct-zol RNA MiniPrep Kit (Zymo 
Research, Irvine, CA, USA) according to manufacturer’s instructions. 
DNA methylation assessment and analysis 
500 ng of g nomic DNA was bisulfite converted with the EZ DNA Methylation Kit (Zymo 
Research, Irvine, CA, USA) and used as input for the Infinium HumanMethylation450 
BeadChip kit (Illumina, San Diego, CA, USA). Initial processing of DNA methylation data 
was conducted using GenomeStudio Methylation Module software (Illumina, San Diego, 
CA, USA) as previously described (12). All samples passed array quality control 
measures prior to analysis. Probe fluorescence intensity values were normalized for all 
samples. An average methylation value was calculated for each probe represented as a 
beta (β) value for all samples and used for subsequent analyses.  
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Bioinformatics analyses of DNA methylation data  
Methylation data were pre-processed using methylumi v2.16.0 R package (13). 
Potential confounding factors were examined, and the race effect was removed using 
ComBat function from sva v.3.18.0 R package (14). Beta values for each methylation 
site were median-averaged for each level of SLEDAI score, and correlation was 
assessed using Pearson correlation coefficient. Adjusting for medication use had 
negligible effect on beta values with results almost identical to unadjusted data, and the 
correlations with SLEDAI scores were also almost identical to the unadjusted analysis. 
Methylation sites correlating with SLEDAI score at p-value < 0.01 were selected. 
Annotation of the locations of methylation sites was performed using ChIPseeker v.1.7.4 
R package (15). Mapping between methylation sites and genes was performed using 
manufacturer-provided annotation file. Functional enrichment analysis in Gene Ontology 
categories and KEGG canonical pathways was performed using GOStats v.2.36.0 R 
package (16). 
Chromosome-centric and transcription factor binding sites enrichment analyses were 
performed using GenomeRunner tool (17). Briefly, for chromosome-centric enrichment 
analysis, genomic locations (hg19) of methylation sites positively/negatively correlating 
with SLEDAI scores were tested for enrichment within each chromosome using Fisher’s 
exact test. For transcription factor binding sites enrichment analysis, genomic locations 
of 161 transcription factors were extracted from the wgEncodeRegTfbsClusteredV3 
supertrack from the UCSC genomic database (18). Genomic locations of all methylation 
sites on the 450K array were used as the reference point to calculate the statistical 
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significance of all identified genomic feature enrichments. All reported p-values are 
multiple testing corrected using False Discovery Rate (FDR) (19).  
Literature analysis was conducted using IRIDESCENT (20), which uses a thesaurus of 
concepts (genes, diseases, phenotypes, chemicals, ontology categories, etc) to identify 
terms asso iated with these concepts within MEDLINE records. Co-mentions of terms 
are summed, with sentence co-mentions receiving a weight of 0.8 and abstract co-
mentions receiving a weight of 0.5. Weights are based on previous studies of the 
probability a co-mention refers to a non-trivial relationship. The top 100 loci with the 
strongest correlations with SLEDAI were then analyzed, with 66 of the positively 
correlated loci being proximal to a gene and 69 of the negatively correlated loci being 
proximal to a gene. Gene lists along with associated concepts were analyzed with 
IRIDESCENT for their connectedness. Unconnected genes are not shown in the graph 
to reduce clutter. 
RNA sequencing and analysis 
A subset of 12 patients enrolled in the study had total RNA extracted for mRNA 
sequencing. The subset had an average age of 42 years and mean and median 
SLEDAI scores of 3 and 2.5, respectively. A sequencing library was created using the 
TruSeq Stranded mRNA library kit (Illumina, San Diego, CA, USA) from purified total 
RNA and 100bp, single-end mRNA reads were sequenced on the HiSeq 2500 
sequencer (Illumina, San Diego, CA, USA). Sequenced reads were cleaned using the 
Trimmomatic-0.32 pre-processing workflow and then mapped to the human genome 
(hg19) with SHRiMP (version 2.2.3) (21, 22). Aligned reads for each gene within each 
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sample were scaled to the number of fragments in each sample library as counts per 





The CPM values were used for subsequent analyses. Correlation analysis with SLEDAI 
scores was assessed using Pearson correlation coefficient and median-averaged 
expression values at each SLEDAI score level.   
MicroRNA microarray analysis 
MicroRNA expression levels in a subset of lupus patients (n=16) was assessed using 
the Affymetrix miRNA 4.1 Array Strip (Affymetrix, Santa Clara, CA, USA). This array 
covers over 2,000 premature and 2,500 mature human miRNA sequences. Total RNA 
was isolated from naïve CD4+ T cells of lupus patient as described above. RNA 
sequences were first polyadenylated, then ligated to a biotin-labeled oligomer using the 
FlashTag Biotin HSR RNA Labeling Kit (Affymetrix, Santa Clara, CA, USA). Biotin-
labeled sequences were hybridized to array probes, washed, and stained with 
streptavidin-PE. Biotin/streptavidin-PE fluorescence was measured and used for 
analysis in the Affymetrix Expression Console & Transcriptome Analysis Console 2.0 
software (Affymetrix, Santa Clara, CA, USA). All samples passed signal intensity, 
polyadenylation, and ligation quality control measures. Signal intensities were 
background adjusted and normalized and a log2-transformed expression value for each 
probeset was calculated using a robust multi-array average model (23). These 
expression values were used for subsequent analyses. Correlation between miR-101 
and miR-26a expression and SLEDAI scores was assessed using Pearson correlation 
coefficient and median-averaged expression values at each SLEDAI score level.   
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We identified 4,839 methylation sites and 1,568 methylation sites that negatively and 
positively correlated with disease activity in lupus, respectively, as measured by 
SLEDAI scores. The distribution of these methylation sites relative to transcription start 
sites and gene structures within the genome is depicted in Figure 1A. Compared to all 
methylation sites included on the 450K methylation array, methylation sites that 
negatively correlated with disease activity in lupus were enriched on chromosome 3, 17, 
and 1 (P= 3.50E-3, 2.98E-3, and 6.67E-3, respectively). Methylation sites that 
correlated positively with disease activity were enriched on chromosome X (P= 2.15E-4) 
(Figure 1B and 1C).  
Transcription factor binding sites analysis revealed that methylation sites positively 
correlating with disease activity in lupus are most significantly enriched for binding sites 
of two repressive transcription factors, EZH2 (P = 1.06E-100) and SUZ12 (P = 3.24E-
74), both are members of the polycomb repressive complex-2 (PRC2). DNA methylation 
sites with methylation levels negatively correlating with disease activity were enriched in 
binding sites for BATF, FOS, CEBPB, JUN, and STAT3 (P = 1.21E-53, 2.44E-53, 
4.63E-50, 6.36E-45, and 7.10E-38, respectively). In contrast to positively correlated 
methylation sites, methylation sites that demonstrate reduced methylation level with 
disease activity are significantly depleted in EZH2 binding sites (P= 5.80E-102) (Figure 
1D). This suggests that the key transcriptional regulator EZH2, which possess 
repressive activity, might be playing a key role in the T cell epigenetic conformational 
changes that predispose to disease flare in lupus. Indeed, literature mining analysis (20) 
independently identified an association between genes nearest the highest SLEDAI-
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correlated methylation sites and EZH2. The negatively correlated genes were highly 
associated (P <0.0001 by 2-tailed Chi-square test with Yates correction) whereas the 
positively correlated genes did not quite reach significance (P <0.07). This analysis also 
demonstrates a pro-inflammatory epigenetic landscape change in naïve CD4+ T cells 
as the disease becomes more active (Figure 2).  
EZH2 expression in T cells has been recently shown to be inhibited by glucose 
restriction, via increased expression of miR-101 and mi-26a which target EZH2 (24). As 
CD4+ T cells in lupus patients demonstrate enhanced glycolysis (25), we hypothesized 
that EZH2 dysregulation upon lupus flares might be mediated by changes in miR-101 or 
miR-26a expression. We measured the expression of miR-101 and miR-26a microRNA 
species in a subset of lupus patients and show an overall negative correlation between 
these microRNAs and disease activity in lupus, and a significant negative correlation 
between miR-26a-2-3p levels in naïve CD4+ T cells and disease activity (r= -0.86, P= 
0.028, Figure 3, supplementary table 1). This microRNA expression pattern is 
consistent with increased activity of EZH2 in naïve CD4+ T cells with lupus flares, 
predicted by our bioinformatics analyses.    
To better understand the nature of the epigenetic change in naïve CD4+ T cells that 
occurs upon lupus flare, we performed a functional enrichment analysis for genes that 
demonstrate reduced methylation (negatively correlated) and increased methylation 
(positively correlated) with disease activity. Genes with methylation levels that 
negatively correlated with SLEDAI scores in lupus were represented in several immune-
related pathways including asthma, allograft rejection, autoimmune thyroid disease, and 
graft-versus-host disease. These pathways seem to have several cytokines in common 
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including the Th2 cell cytokine genes IL4, IL5, and IL13, as well as several HLA class II 
genes (Table 1). Genes with methylation levels that positively correlated with SLEDAI 
scores were enriched in several pathways, most notably the inhibitory TGF-beta 
signaling pathway (Table 1).  
To further characterize epigenetic changes that might influence T cell differentiation in 
naïve CD4+ T cells upon increased disease activity, we performed a gene ontology 
analysis focused on “cytokine” related ontologies that are enriched in genes with 
methylation levels negatively and positivity correlated with disease activity 
(Supplementary table 2). These analyses showed significant enrichment in cytokine 
related ontologies in negatively correlated genes, with a pattern most consistent with an 
epigenetic shift towards a Th2 and possibly Th17 response, suggested by reduced 
methylation in key cytokine genes such as IL4, IL5, IL13, IL12B, and IL17F when 
disease activity is increased in lupus. Indeed, the gene ontology for Th2 cytokine 
production was the most enriched ontology among genes hypomethylated with disease 
activity (odds ratio= 17.5, P= 2.04E-02). Other inflammatory T cell cytokine genes that 
show reduced methylation levels with disease activity include IL9 and IL22. In contrast, 
genes with methylation levels that increase with disease activity include inhibitory 
cytokine genes including TGF-beta related genes.  
We next examined DNA methylation changes in key CD4+ T cell subsets transcription 
factors. Our data show reduced methylation with disease activity in the genes encoding 
PU.1, RORγt, and BCL-6, which promote Th9, Th17, and Tfh cell responses, 
respectively. Genes encoding critical Tfh cell molecules such as ICOS and CXCR5 
were also hypomethylated with increased disease activity in lupus, while no methylation 
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change with disease activity was observed in IL21. Genes encoding the Th1 and Th2 
transcription factors T-bet and GATA3 showed hypermethylation with disease activity in 
lupus (Figure 4).  
To determine if this “epigenetic shift” towards an activated T cell phenotype precedes T 
cell activation and differentiation, we performed RNA sequencing in a subset of naïve 
CD4+ T cells included in this study. The majority of genes that showed DNA methylation 
changes negatively or positively correlating with disease activity in lupus demonstrated 
no significant change in gene expression levels with disease activity. This observation is 
not unexpected and is consistent with the naïve phenotype of the examined T cells, and 
also indicates that epigenetic changes that favor T cell activation predate gene 
expression changes. This is shown for the Th2 cytokine genes and the transcription 
factor NFkB in Figure 5. Therefore, our data suggest that a pro-inflammatory 
epigenomic remodeling in naïve CD4+ T cells is an early event occurring with increased 
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In this study we demonstrate that an epigenetic landscape remodeling in naïve CD4+ T 
cells is associated with disease activity in lupus patients. With increased disease 
activity, as reflected by higher SLEDAI scores, naïve CD4+ T cells undergo an 
epigenetic shift that predisposes to an active T cell phenotype, evident at the naïve 
CD4+ T cells stage before T cell differentiation and activation. Indeed, by examining 
naïve CD4+ T cells we can predict early changes in T cell composition that accompany 
disease flares. Arguably, these compositional changes might be triggering or at least 
contributing to the initiating events resulting in a lupus flare.  
The nature of the epigenetic shift detected suggests hypomethylation of genes involved 
in T cell activation and differentiation, and hypermethylation in inhibitory signaling 
pathways such as TGF-beta. Genes that demonstrate reduced methylation with 
increased disease activity in naïve CD4+ T cells from lupus patients include Th2 
signature genes such as IL4, IL5, and IL13. Th2 cytokine gene hypomethylation is 
observed despite a paradoxical methylation increase in GATA3, suggesting that 
epigenetic poising of the Th2 cytokine gene locus with lupus flares is independent of the 
methylation status of GATA3. Negative correlation between DNA methylation in IL12B, 
IL17F, and RORC (encoding RORγt) and disease activity in lupus suggests that a Th17 
response might be also an early event in lupus flares. Similarly, negative correlation 
between DNA methylation in the genes encoding BCL-6, ICOS, and CXCR5, and PU.1 
and IL-9, suggests a role for Tfh and Th9 responses, respectively, in lupus flares. In 
contrast, no epigenetic changes were detected in or near the gene encoding for IFNγ, 
which is they key Th1 cytokine gene that typically gets demethylated upon Th1 
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differentiation. In addition, genes encoding other Th1 response molecules such as 
lymphotoxin (LT)-α, and LT-β, and the Th1 key transcription factor T-bet showed 
increased methylation with disease activity, and therefore are predicted to be 
epigenetically silenced with lupus flares. These data suggest that a non-Th1 response is 
the likely early T cell event occurring with increased disease activity in lupus, and 
underscores T cell-dependent B cell activation and plasma cell expansion in lupus 
flares.  
The relative importance of Th2, Th17, or Tfh cell differentiation as an early flare event in 
lupus patients remains unclear, and is also complicated by the possibility of a transient 
role of these T cell responses in initiating disease relapse. Once a flare is established, it 
is possible that multiple other immune signaling and activating pathways become 
involved, which might or might not mask a predicted role for non-Th1 immune 
responses suggested by our data. These epigenetic changes occur without 
corresponding transcriptional changes indicating that a change in the epigenetic 
landscape in CD4+ T cells is an early event in lupus flares. The master pro-
inflammatory cytokine regulator gene encoding for NFkB also is progressively 
demethylated with increased disease activity in lupus CD4+ T cells. In contrast, 
inhibitory pathways such as TGF-beta signaling are more methylated in active disease. 
Taken together, these data suggest that an epigenetic remodeling event shifting naïve 
CD4+ T cells towards activation and non-Th1 effector T cell differentiation and away 
from Treg differentiation could predispose to lupus flares. 
To understand possible upstream events that might contribute to this epigenetic shift in 
naïve CD4+ T cells during disease flare, we determined if common transcription factors 
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might be involved in regulating genes with methylation levels that positively or 
negatively correlated with disease activity in lupus. We found a robust enrichment for 
binding sites of the transcription factor EZH2 in methylation sites positively correlated 
with disease activity. Interestingly, methylation sites that are negatively correlated with 
disease activity are depleted of EZH2 binding sites. EZH2 is the catalytic member of the 
polycomb repressive complex-2 (PRC2). It encodes a histone methyltransferase, which 
methylates lysine 27 in histone H3, resulting in transcriptional repression and it can also 
recruit DNA methyltransferases including DNMT1, DNMT3A, and DNMT3B (26, 27). 
PRC2 and EZH2 play an important role in X-chromosome inactivation (28, 29), which 
might explain the relative enrichment of methylation sites that positivity correlated with 
disease activity in lupus on the X-chromosome. EZH2 plays an essential role in CD4+ T 
cell plasticity and differentiation. EZH2 has been implicated in the transcriptional 
silencing of Th2 cytokine genes, while EZH2 deficiency was shown to reduce Th1 
differentiation by reducing the expression of T-bet and STAT4 (30, 31). However, other 
studies have shown that under Th1, Th2, and Th17 differentiation conditions, EZH2 
deficiency enhances IFN-γ, IL-13, and IL-17 production, respectively (32). Further, 
EZH2 is critical in maintaining Treg function during T cell activation and differentiation, 
and EZH2 deficiency has been demonstrated to reduce Treg differentiation (32). 
Interestingly, EZH2 deficient Tregs as well as effector T cells demonstrate functional 
defects. Effector T cells deficient in EZH2 failed to expand in culture and to induce 
autoimmunity in a colitis model, and failed to protect against T.gondii infection which is 
known to elicit a Th1 response (32). In contrast, EZH2 deficiency enhanced Th2 
responses in vivo in an asthma mouse model (33). Taken together, these data suggest 
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a complex, sometimes contradictory, but crucial role for EZH2 in T cell responses. 
Indeed, recent studies suggest that EZH2+ T cells are polyfunctional expressing 
multiple effector cytokines, and that EZH2 expression is increased with T cell activation 
and enhances T cell survival and effector function by inhibiting Notch signaling 
repressors (24).  
Recent evidence suggests that EZH2 expression is sensitive to glucose availability. 
Glucose restriction suppresses EZH2 expression by inducing the expression of two 
microRNAs that target EZH2 (miR-101 and miR-26a) (24). Consistent with our model of 
lupus flares, we find negative correlation between miR26a expression and disease 
activity in lupus patients. This suggests that reduced microRNA regulation of EZH2, 
possibly mediated by increased glycolysis and glucose availability, might result in 
transient increase in EZH2 activity leading to epigenetic reprograming in T cells favoring 
T activation. This model is consistent with recent reports showing enhanced glycolysis 
in CD4+ T from lupus patients and lupus mouse models (25).  It should be noted that we 
did not observe a correlation between EZH2 mRNA expression levels and disease 
activity in naïve CD4+ T cells in lupus (data not shown). This might be explained by the 
sometimes transient nature of gene expression changes which in this case could have 
been missed as the epigenetic changes presumably resulting from EZH2 have been 
already established in naïve CD4+ T cells.  
In summary, we provide evidence for epigenetic changes in CD4+ T cells in lupus that 
suggests a role for T cell activation and non-Th1 functions as early contributing immune 
responses in lupus flares. These epigenetic changes might be mediated by EZH2 which 
is an epigenetic regulator that is sensitive to glucose availability and plays an important 
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role in T cell plasticity, activation, and differentiation. Further studies into the direct role 
of EZH2 in lupus progression and flares are warranted.  
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Figure 1: Annotation of the locations of methylation sites that positively and negatively 
correlate with SLEDAI scores in lupus patients (upper and lower panels, respectively) 
relative to transcription start sites and gene structures (A). Enrichment by chromosome 
analysis of DNA methylation sites negatively correlated (B) and positively correlated (C) 
with disease activity as measured by SLEDAI scores in lupus patients. Y-axis shows 
FDR corrected enrichment p-values, X-axis shows chromosome numbers, sorted by 
most to least enrichments. (D) Heatmap of transcription factor binding sites (Y-axis) 
enriched in DNA methylation sites negatively and positively correlating with SLEDAI 
score (X-axis). Blue/yellow/red gradient shows significance of depletion/enrichment, 
respectively. Top 30 transcription factors most differentially enriched between the two 
sets of methylation sites are shown. 
Figure 2: Literature analysis of how concepts (yellow) are connected to genes whose 
methylation status is positively (green) and negatively (red) correlated with SLEDAI 
scores. The top 100 positively and negatively correlated methylation sites were included 
in this analysis. Existence of an edge indicates that the two nodes appear together in 
MEDLINE titles/abstracts at least 3 times, while thickness of the line correlates with 
frequency of the two terms being co-mentioned. Edges linking concepts and genes are 
shaded gray, while edges linking genes are black.  
Figure 3: MicroRNA expression levels of miR-101 and miR-26a in naïve CD4+ T cells 
from lupus patients. Median values for each SLEDAI level are depicted for miR-101 and 
miR-26a probes with a Pearson correlation (r) with SLEDAI scores of ≥ │0.50│. The 
negative correlation between miR-26a-2-3p levels and SLEDAI scores was statistically 
significant (r=-0.86, P= 0.028). Two probe sets for each miR-101-1 and miR-26a-1 were 
included.   
Figure 4: Schematic representation of DNA methylation changes with disease activity in 
lupus naïve CD4+ T cells in key effector CD4+ T cell subsets genes.   
Figure 5: Negative correlation between DNA methylation in Th2 cytokine genes (IL4, 
IL5, and IL13) and NFKB1 in naïve CD4+ T cells and disease activity in lupus patients 
(red) (r= -0.74, -0.74, -0.83, and -0.94; P= 0.0095, 0.0092, 0.0017, and 1.36E-05, 
respectively). Reduced methylation levels with disease flares in these genes precede 
active transcription as evidenced by lack of correlation between mRNA levels measured 
using RNAseq with disease activity (blue) (P= 0.15, 0.81, 0.63, and 0.78, respectively).  
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Table 1: Pathway analysis for genes with DNA methylation changes that negatively or 
positively correlated with disease activity in naïve CD4+ T cells in lupus 
 
Genes with negative correlation between methylation status and disease activity in lupus 
Pathway Odds 
Ratio 
P value (FDR 
adjusted) 
Genes 
Asthma 8.49 2.67E-06 IL13,IL4,IL5,HLA-DMB,HLA-DPA1,HLA-DRB1,HLA-DQA2,HLA-
DMA,FCER1G,RNASE3,FCER1A,IL9,HLA-DQA1,HLA-DPB1,HLA-DRB5,IL3,CD40 





















    
Genes with positive correlation between methylation status and disease activity in lupus 
Pathway Odds 
Ratio 
P value (FDR 
adjusted) 
Genes 
















6.07 1.03E-02 B3GAT1,CHST11,DSE,CHSY1,CHST13 
Phosphatidylinositol 
signaling system 
3.06 1.03E-02 DGKZ,INPP5A,ITPR3,PIK3CD,PIP4K2A,ITPKB,DGKA,PLCB1,INPP4A,PLCG1 
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Multiple probe sets were included and evaluated for some miRNA species
Supplementary Table 1: Correlation between miR-101 and miR-26a 
expression in naïve CD4+ T cells with disease activity (SLEDAI) in 
lupus patients
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Supplementary Table 2: "Cytokine"-related gene ontologies
Gene Ontology ID Gene Ontology Term Odds 
Ratio
P  value (FDR 
adjusted)
Genes
GO:0035745 T-helper 2 cell cytokine production 17.47 2.04E-02 PRKCZ,IL4,XCL1
GO:0035743 CD4-positive, alpha-beta T cell cytokine 
production
8.73 3.24E-02 PRKCZ,IL4,XCL1
GO:0032466 negative regulation of cytokinesis 7.77 2.04E-02 ZFYVE19,AURKB,E2F7,VPS4A
GO:0002726 positive regulation of T cell cytokine production 3.88 4.73E-02 PRKCZ,SASH3,XCL1,TRAF2
GO:0002369 T cell cytokine production 3.71 2.01E-02 PRKCZ,IL4,DLG1,SASH3,XCL1,TRAF2,SLC11A1



















GO:0002367 cytokine production involved in immune response 1.90 3.81E-02 PRKCZ,IL4,DLG1,FCER1G,SASH3,APOA2,XCL1,TRAF2,IRAK3
,TGFB2,SLC11A1,ATG5,TREM1,BCL6
GO:0042107 cytokine metabolic process 1.88 1.29E-02 IL12B,IL4,ZFPM1,IL19,CD86,IL6,IL17F,EBI3,AZU1,CARD9,SF
TPD,APOA2,BCL3,CEBPE,FOXJ1,IGF2BP3,FCER1A,IL9,TNFR
SF8,STAT5B,INHBA,TREM1,IL18,IL27,CD80,NFKB1
GO:0042089 cytokine biosynthetic process 1.87 1.46E-02 IL12B,IL4,ZFPM1,IL19,CD86,IL6,IL17F,EBI3,AZU1,CARD9,SF
TPD,APOA2,BCL3,CEBPE,FOXJ1,IGF2BP3,FCER1A,IL9,TNFR
SF8,STAT5B,INHBA,IL18,IL27,CD80,NFKB1
GO:0042035 regulation of cytokine biosynthetic process 1.84 2.21E-02 IL12B,IL4,ZFPM1,CD86,IL6,IL17F,EBI3,AZU1,CARD9,SFTPD,
APOA2,BCL3,FOXJ1,IGF2BP3,FCER1A,IL9,TNFRSF8,STAT5B,
INHBA,IL27,CD80,NFKB1


















Genes with negative correlation between methylation status and disease activity in lupus
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Gene Ontology ID Gene Ontology Term Odds 
Ratio
P  value (FDR 
adjusted)
Genes
GO:0002718 regulation of cytokine production involved in 
immune response
2.55 4.53E-02 F2RL1,C10orf54,SEMA7A,TRIL,PRKCZ,TGFB2
Genes with positive correlation between methylation status and disease activity in lupus
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GO:0005126 cytokine receptor binding 1.88 1.80E-02 DAB2IP,SMAD3,EPO,KITLG,ITGA5,IL6ST,CNTF,NGF,GATA3,
SMURF2,BMP4,TGFBR2,TMBIM1,CCL28,VEGFB,LTA,LTB,T
GFB2,EDA,TNFSF11,PLCG1,TGFBR1
Page 33 of 33
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
